Atenolol in essential hypertension during pregnancy. 1990

D J Cruickshank, and D M Campbell

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007741 Labetalol A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS. AH-5158,Albetol,Apo-Labetalol,Dilevalol,Labetalol Hydrochloride,Labetalol, (R,R)-Isomer,Labetolol,Normodyne,Presolol,R,R-Labetalol,SCH-19927,Trandate,AH 5158,AH5158,Apo Labetalol,ApoLabetalol,Hydrochloride, Labetalol,R,R Labetalol,SCH 19927,SCH19927
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011249 Pregnancy Complications, Cardiovascular The co-occurrence of pregnancy and a cardiovascular disease. The disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS. Cardiovascular Pregnancy Complications,Complications, Cardiovascular Pregnancy,Pregnancy, Cardiovascular Complications,Cardiovascular Pregnancy Complication,Complication, Cardiovascular Pregnancy,Pregnancies, Cardiovascular Complications,Pregnancy Complication, Cardiovascular
D005260 Female Females
D005317 Fetal Growth Retardation Failure of a FETUS to attain expected GROWTH. Growth Retardation, Intrauterine,Intrauterine Growth Retardation,Fetal Growth Restriction,Intrauterine Growth Restriction
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001262 Atenolol A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect. ICI-66082,Tenormin,Tenormine,ICI 66082,ICI66082

Related Publications

D J Cruickshank, and D M Campbell
September 1990, BMJ (Clinical research ed.),
D J Cruickshank, and D M Campbell
August 1982, British journal of clinical pharmacology,
D J Cruickshank, and D M Campbell
February 1984, The British journal of clinical practice,
D J Cruickshank, and D M Campbell
May 1976, Clinical pharmacology and therapeutics,
D J Cruickshank, and D M Campbell
January 1981, European journal of clinical pharmacology,
D J Cruickshank, and D M Campbell
January 1994, The American journal of cardiology,
D J Cruickshank, and D M Campbell
January 1983, Acta medica Scandinavica. Supplementum,
D J Cruickshank, and D M Campbell
February 1992, Hypertension (Dallas, Tex. : 1979),
D J Cruickshank, and D M Campbell
September 1986, Canadian family physician Medecin de famille canadien,
D J Cruickshank, and D M Campbell
May 1981, La Clinica terapeutica,
Copied contents to your clipboard!